It remains to be seen whether Seroquel will be the product liability bonanza plaintiffs lawyers predict. But one's things for sure: In Delaware state court, the litigation has been a dud.

With summary judgment granted to AstraZeneca in another Seroquel case last week--the third Seroquel suit to be tossed on Daubert grounds--the Delaware state court judge overseeing a docket of 700 of the pharmaceutical product liability cases says it's time for plaintiffs' lawyers to consider the viability of the litigation.

So far, AstraZeneca has spent almost $750 million defending claims that the antipsychotic causes diabetes, most recently, according to Bloomberg, settling 6,000 cases for an average $25,000 each. Weitz & Luxenberg, however, insists its 2,400 cases won't go away until AZ comes up with better offers than that.

Gibson Dunn's Ted Olson suffered a big loss at the hands of his successor as Bush-era solicitor general, Paul Clement of Bancroft.